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Modern molecular and radiopharmaceutical development has brought the promise of 
tumor-selective delivery of antibody–drug conjugates to tumor cells for the diagnosis 
and treatment of primary and disseminated tumor disease. The classical mode of dis-
course regarding targeted therapy has been that the antigen targeted must be highly 
and homogenously expressed in the tumor cell population, and at the same time exhibit 
low expression in healthy tissue. However, there is increasing evidence that the reason 
cancer patients are not cured by current protocols is that there exist subpopulations of 
cancer cells that are resistant to conventional therapy including radioresistance and that 
these cells express other target antigens than the bulk of the tumor cells. These types of 
cells are often referred to as cancer stem cells (CSCs). The CSCs are tumorigenic and 
have the ability to give rise to all types of cells found in a cancerous disease through the 
processes of self-renewal and differentiation. If the CSCs are not eradicated, the cancer 
is likely to recur after therapy. Due to some of the characteristics of alpha particles, such 
as short path length and high density of energy depositions per distance traveled in 
tissue, they are especially well suited for use in targeted therapies against microscopic 
cancerous disease. The characteristics of alpha particles further make it possible to 
minimize the irradiation of non-targeted surrounding healthy tissue, but most importantly, 
make it possible to deliver high-absorbed doses locally and therefore eradicating small 
tumor cell clusters on the submillimeter level, or even single tumor cells. When alpha par-
ticles pass through a cell, they cause severe damage to the cell membrane, cytoplasm, 
and nucleus, including double-strand breaks of DNA that are very difficult to repair for 
the cell. This means that very few hits to a cell by alpha particles are needed in order 
to cause cell death, enabling killing of cells, such as CSCs, exhibiting cellular resistance 
mechanisms to conventional therapy. This paper presents and evaluates the possibility 
of using alpha-particle emitting radionuclides in the treatment of prostate cancer (PCa) 
and discusses the parameters that have to be considered as well as pros and cons of 
targeted alpha-particle therapy in the treatment of PCa. By targeting and eradicating the 
CSCs responsible of tumor recurrence in patients who no longer respond to conventional 
therapies, including androgen deprivation and castration, it may be possible to cure the 
disease, or prolong survival significantly.
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prostate CanCer (pCa)
Cancer is a leading cause of death worldwide, with more than 8.2 
million deaths in 2012, and PCa is the leading cause of cancer-
related deaths among males1. When localized, PCa may be cured 
by surgery; however, once PCa has become metastatic, androgen-
deprivation therapy (ADT) is the mainstay first-line therapy with 
clinical improvements in more than 90% of patients. However, 
ADT is not curative; cancer control and palliation only lasts for 
about 18−24 months until the tumor becomes castration resistant 
(CRPC) (1).
Until recently, few treatment options were available for meta-
static CRPC. However, during recent years, there has been a rapid 
increase in the number of novel therapies, including the androgen 
synthesis inhibitor abiraterone, the antiandrogen enzalutamide, 
the chemotherapeutic taxane cabazitaxel, immunotherapeutic 
sipuleucel-T, and 223Ra-dichloride (Xofigo®) targeting active 
bone cells due to its similarity to calcium (2, 3). 223Ra-dichloride is 
sometimes referred to as a targeted alpha-particle therapy (TAT), 
although the concept most often is used when alpha particles are 
directly targeted to the malignant cells in question. Despite recent 
survival improvements for men with metastatic CRPC, this dis-
ease stage remains incurable. Understanding the biology behind 
drug resistance development and the CRPC stage is of crucial 
importance if we are to identify and develop new treatment strat-
egies as well as better prognostic and predictive biomarkers for 
this patient group. Current challenges include both monitoring 
when CRPC develops and to develop novel therapies that could 
treat this fatal stage. CRPC is usually suspected in patients with 
a rising prostate-specific antigen level, or with new evidence of 
disease on a 99mTc-medronic acid-based bone scintigraphy scan. 
99mTc-medronic acid is a phosphate derivate that can replace bone 
phosphate in areas with reactive bone tissue due to metastases, 
and bone scintigraphy is the standard procedure for the detection 
of bone metastases. However, targeted radionuclide pharmaceu-
ticals, for either diagnosis or therapy, may instead specifically 
target malignant metastatic cells, and regardless of localization 
(bone or soft tissue), more accurately stage or treat metastatic 
lesions and better detect relapsed disease, monitor development 
of CRPC, and predict the aggressiveness of the disease. Novel radi-
opharmaceuticals may also be developed and used for theranostic 
purposes, i.e., combined imaging (or multimodal imaging) and 
therapy utilizing, for example, single-photon emission computed 
tomography, positron emission tomography, magnetic resonance 
imaging, ultrasound imaging, Cherenkov luminescence imaging, 
or photoacoustic imaging, in conjunction with a radioimmuno-
therapy (RIT)-based (using, for example, beta- or alpha-particle 
emitters) treatment.
To date, the only prognostic PCa biomarker approved by 
the US Food and Drug Administration is circulation tumor cell 
counts (CTCs) (4). One may envision that genomic or proteomic 
profiling of relapsing CTCs can provide novel prognostic or 
predictive biomarkers to aid in the development of whole-organ 
and body imaging and therapy of CRPC patients.
1 Globocan. Available from: http://globocan.iarc.fr.
resistanCe and CanCer steM  
CeLLs (CsCs)
The development of CRPC and resistance as well as metastatic 
spread likely involves reactivation/activation of the cells that 
initiate metastasis, the CSCs. These are cells that are thought to 
have the ability to spread to and infiltrate other organs where 
they can establish dormant or fully fledged tumors, survive, 
self-renew, and interact with the niche to support daughter cell 
proliferation and differentiation to recapitulate the cell types of 
the original tumor (5). Thus, the CSC concept provides a model 
for the phenotypic and functional heterogeneity found in PCa 
tumors (6). The model may also explain why patients are not 
cured when treated with standard therapies—small subpopula-
tions of cancer cells survive because they do not at all, or not 
to any substantial degree, express the biomarker or pathway of 
the more differentiated cells that are targeted. Alternatively, the 
targeted pathways are wired differently in the CSC population. 
Further, CSCs are believed to show increased radio- and chem-
oresistance due to increased expression of antiapoptotic proteins, 
DNA repair genes, and transporter proteins such as ATP-binding 
cassette (ABC) proteins and aldehyde dehydrogenase (ALDH) 
genes (7).
On a molecular level, it is clear that progression to CRPC is 
characterized by an active androgen pathway, despite systemic 
androgen deprivation, and despite the new repertoire of thera-
peutic options available today, there is an increase in intratumoral 
androgen biosynthesis, aberrant androgen receptor (AR) expres-
sion, cross talk with other oncogenic pathways, reactivation 
of epithelial–mesenchymal transition (EMT) processes, and 
upregulation of genes that regulate stemness and self-renewal (8). 
The co-expression of AR and several stem cell (SC) markers in 
CRPC suggest that the AR is aberrantly reactivated together with 
deregulation of epigenetic mechanisms controlling self-renewal 
or lineage commitment of SCs. The AR recruits corepressors 
and histone deacetylases (HDACs) to promoters and thereby 
re-organizes the chromatin structure to epigenetically modulate 
transcription of genes that control proliferation and differentia-
tion (9).
Whether CSCs arise from mutated adult tissue SCs, or if CSCs 
arise from differentiated/lineage committed progenitor cells by 
means of mutation or epigenetic change to function as a cancer-
initiating cell in prostate carcinogenesis and progression is not 
known. By mutation of pathways that control self-renewal, dif-
ferentiation may lead to increased stemness. It has, for example, 
been suggested that induced pluripotent stem cell technology 
could occur naturally by means of mutation or upregulation of 
genes that induce or maintain plasticity to reprogram cells into 
a pluripotent state (10). The EMT process is not only involved in 
embryogenesis but also involved in tissue repair. During the EMT 
process, cells acquire mesenchymal properties and it has been 
reported that EMT is mechanistically linked with SC signatures 
in PCa cells (11). However, no standardized CSC markers have 
been established for PCa, or other solid tumors, and different 
researchers use different surface biomarkers or assays for the 
investigation of putative CSC biology. Better identification and 
characterization of normal SCs and CSCs may allow screening of 
taBLe 1 | alpha-particle emitting radionuclides possible to use for tat 
against cancer stem cells (CsCs).
radionuclide energya (keV) rangeb 
(μm)
Letc (keV/μm) Half-lifed
Astatine-211 (211At)e 7,450 (6,786) 66 (57) 71−240 (125) 7.2 h
Bismuth-212 (212Bi)f 8,785 (7,804) 86 (71) 63−240 (120) 60.6 min
Bismuth-213 (213Bi)g 8,377 (8,325) 80 (79) 65−240 (120) 45.6 min
Radium-223 (223Ra)h 7,386 (6,595) 65 (54) 71−240 (125) 11.4 d
Actinium-225 (225Ac)i 8,377 (6,877) 80 (58) 65−240 (120) 10.0 d
Thorium-227 (227Th)j 7,386 (6,458) 65 (53) 71−240 (125) 18.7 d
Alpha-particle energy, range and linear energy transfer (LET) in soft tissue, and physical 
half-life are stated.
aMost abundant alpha-particle energy. Approximate average energy in parenthesis. 
During the 225Ac decay chain, a 7067 MeV particle is approximately as abundant as the 
8377 MeV particle stated.
bRanges in soft tissue (e.g., skeletal muscle and prostate; 1.04 g/cm3) of most 
abundant-energy (and average-energy) alpha particles. Calculated with James Ziegler’s 
SRIM-2013 software.
cInterval of most abundant alpha particle, from initial value to Bragg peak. Approximate 
average LET in parenthesis. Calculated using James Ziegler’s SRIM-2013 software.
dAbbreviations: d, days; h, hours; min, minutes.
eBoth decay routs from 211At to 211Po and 207Bi taken into account.
fBoth decay routs from 212Bi to 212Po and 208Tl taken into account.
gBoth decay routs from 213Bi to 213Po and 209Tl taken into account.
hDecay chain from 223Ra to 211Po and 207Tl taken into account.
iDecay chain from 225Ac to 213Po and 209Tl taken into account.
jDecay chain from 227Th to 213Po and 209Tl taken into account.
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CSC genes or cellular products, including cell surface biomarkers, 
transcription factors, microRNAs, and exosomes.
tarGeted aLpHa-partiCLe rit
The most successful clinical application of RIT has until today 
been achieved by using the beta-particle emitting radionuclides 
90Y or 131I labeled to monoclonal antibodies (mAbs) in the 
treatment of CD20 expressing follicular B-cell non-Hodgkin’s 
lymphoma (12). However, regarding RIT treatment of solid 
cancers, e.g., as adjuvant therapy after primary surgery and/or 
chemotherapy, there has been limited success. And so far, there is 
only one FDA approved radionuclide-based drug against PCa as 
mentioned previously; 223Ra-dichloride (Xofigo®), although not a 
RIT approach since the alpha-particle emitter 223Ra is not labeled 
to any mAb.
Targeted alpha therapy (TAT), in which an alpha-particle 
emitting radionuclide is labeled to a molecular carrier targeting 
a specific tumor antigen, differs from standard radioimmuno-
therapeutic approaches emitting beta particles. The quantum 
mechanical tunneling phenomena enabling the alpha-particle 
decay results in the release of a highly energetic and heavy alpha 
particle, consisting of two protons and two neutrons, from the 
atomic nucleus. If released in tissue, an alpha particle deposit its 
entire kinetic energy along a 60−90 μm short track, i.e., in the 
range of only three to six cell diameters. This short range makes 
alpha particles especially well suited for targeting small tumor cell 
clusters, or even single tumor cells, and when trying to minimize 
irradiating non-targeted surrounding healthy tissue. The high 
frequency of energy deposits within such a short range means a 
high linear energy transfer (LET), expressed as kiloelectronvolts 
per micrometer (keV/μm). The five alpha-particle emitters most 
often used in TAT so far, and that would be suitable for TAT 
against CSCs, are Actinium-225 (225Ac), Radium-223 (223Ra), 
Bismuth-213 (213Bi), Bismuth-212 (212Bi), and Astatine-211 
(211At). Actinium-225 emit four alpha particles in a serial decay 
and have good therapeutic potential, especially if radiochemis-
try can produce stable binding of 225Ac and its daughters to the 
carrier molecule and/or the 225Ac radioimmuno-complex can 
be rapidly internalized. Radium-223 emits four alpha particles 
and two beta particles in its decay chain and has been used in 
the form of 223Ra-dichloride against skeletal PCa metastases as 
mentioned above. This nuclide can be produced via neutron 
activation of 226Ra. Bismuth-213 emits one alpha particle and can 
be obtained by the elution of a 225Ac/213Bi generator produced 
by, for example, the Institute for Transuranium Elements in 
Karlsruhe, Germany (13). Bismuth-212 emits one alpha particle 
and one beta particle during its decay. A high-energy gamma 
ray of 2.6 MeV is accompanying the alpha and beta decay via the 
daughter nuclide 208Tl, and therefore, patients must be kept under 
radiation protection conditions if this nuclide is to be utilized. 
If a proper carrier is chelated with its mother nuclide 212Pb, this 
could be used as a vehicle to carry the alpha-particle emitter 212Bi 
to its targets. Astatine-211 emits one alpha particle during either 
one of its two possible decay routes to stable 207Pb. One of this 
nuclide’s favorable characteristics is that its chemistry is similar 
to that of Iodine. Due to the fact that this alpha-particle emitter 
is cyclotron produced, this radionuclide, otherwise highly suit-
able for TAT, has not so far reached its full potential, as only a 
handful of research centers and hospitals have this capability. 
Table  1 presents the abovementioned suitable alpha-particle 
emitters for TAT, together with their most important physical 
characteristics. Table 1 also includes the lists the alpha-particle 
emitter 227Th, which also have properties making it a potential 
TAT nuclide.
High-LET radiation, such as alpha particles (LET ≈ 100 keV/
µm), causes damage to the DNA, e.g., frequent double-strand 
breaks, which are much more difficult to repair by the cell 
than those most commonly caused by low-LET radiation such 
as beta-particles (LET ≈  0.2−0.3  keV/μm), e.g., base damage 
or single-strand breaks. This high-LET characteristic of alpha-
particles makes them independent of oxygenation or active cell 
proliferation in order to sterilize a cell, and very few hits to a cell 
are needed in order to sterilize it compared to beta particles. 
Even one single hit by an alpha particle has a significant chance 
of sterilizing a cell, although most often approximately 20 hits 
are considered to be lethal, compared to approximately 2,000 
beta particles (14). This type of highly cytotoxic type of radia-
tion, directed against specific tumor cell antigens, has therefore 
good chance of substantially adding to hitherto failing curative 
adjuvant treatments for different types of cancer, e.g., prostate, 
breast, colon, and ovarian cancer, and is sometimes referred to 
as systemic conformal radiotherapy at the cellular level. Several 
preclinical studies have been performed using TAT, but until 
today only a limited number of early-stage clinical studies have 
been completed, as mentioned below.
The TAT methodology against recurrent brain tumors 
have been used with the alpha-particle emitters 213Bi and 211At 
4Ceder and Elgqvist Cancer Stem Cell-Targeted Alpha Therapy
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(15, 16). Intraperitoneal TAT in ovarian cancer patients has been 
performed using 211At (17), as well as several preclinical studies 
evaluating this methodology (18–20). Pharmacokinetics and 
imaging in patients using 212Pb-TCMC-Trastuzumab, directed 
against human epidermal growth factor receptor-2-positive 
intraperitoneal ovarian cancer has also been performed (21). 
A  number of studies have been performed using 213Bi or 225Ac 
for the treatment of myelogenous leukemia (22–26). TAT of 
B-lineage non-Hodgkin’s lymphoma using 213Bi-labeled anti-
CD19- and anti-CD20-CHX-A″-DTPA conjugates has also been 
performed in one study (27). Against metastatic melanoma 213Bi 
has been used in two studies (28, 29). And as mentioned above, 
use of 223Ra-dichloride is now approved by the FDA against 
symptomatic skeletal PCa metastases (3).
Regarding the dosimetry of alpha particles, it could under 
some circumstances be challenging, especially considering 
the alpha particle’s short path length and high LET in tissue. 
When the statistical variation of the energy imparted to dif-
ferent cell nuclei caused by alpha particles is high, the average 
absorbed dose could be of little or no value and microdosimetry 
might instead be necessary to apply. Kellerer and Chmelevsky 
suggested already in a paper from 1975 that the stochastic 
variation of the deposited energy within a specified target, i.e., 
microdosimetry, must be taken into consideration in situations 
during which the deviation of a local absorbed dose exceeds 20% 
(30). MIRD Pamphlet No. 22 gives a comprehensive presenta-
tion of alpha-particle radiobiology and dosimetry, and other 
both review and original papers present different aspects of the 
subject (14, 31–34).
tarGeted aLpHa tHerapy aGainst 
prostate CsCs
It is clear from the previous discussion that we cannot allow the 
CSC population to remain untargeted while treating the bulk of 
the tumor, as is currently done using conventional therapies, if 
we are to eradicate the entire tumor burden and prevent relapse. 
However, given that CSCs are more resistant to chemo- and 
radiotherapies, smart design strategies may not only target the 
CSC population but do so more efficiently. By utilizing the TAT 
technology against CSCs, the effect should be more efficient than 
the present use of 223Ra-dichloride, by reaching and targeting the 
malignant cells directly, and specifically the cells responsible for 
tumor recurrence. Treating the bulk of the tumor mass with RIT 
directed against antigens expressed only on the more differenti-
ated cells, and not the CSCs, will probably not deliver a high 
enough absorbed dose to the radio-resistant CSCs. By bringing 
the radionuclide in direct contact with the recurrent CSC, the 
higher expression of antiapoptotic, DNA repair, drug efflux, 
and detoxifying proteins in CSCs that enhanced their survival 
(35) may be overcome if alpha particles are utilized (Figure 1). 
Therefore, supposedly using a cocktail treatment with for exam-
ple a beta-particle emitter such as 90Y directed against the bulk of 
the differentiated tumor cells, creating a relatively homogenous 
absorbed dose distribution within the entire tumor (34), plus an 
alpha-particle emitter such as 211At or 213Bi directed against the 
CSCs, could create a high-absorbed dose region, especially were 
the CSCs are situated, and be highly effective in conventionally 
resistant tumors.
FiGUre 1 | Generalized image showing an antibody–drug complex (1), and a schematic way in which it is targeted to a cancer stem cell (CsC). The 
antibody should be specific for CSC-associated antigens so that its payload, in the shape of a therapeutic agent, is not delivered to normal cells causing unwanted 
side effects. The linker should firmly attach the therapeutic agent to the antibody, enabling delivery of the drug to its target (2), and not being released during 
circulation. The therapeutic agent should be able to kill the targeted CSC when the antibody–drug complex is either bound to the cell surface or internalized in 
sufficient numbers (3). Receptor-mediated endocytosis (4) of the payload (e.g., an alpha-particle emitting radionuclide or a cytotoxic agent) may cause disruption of 
cellular processes (including microtubule networks), mitotic arrest, or cell death due to double-strand breaks of the DNA (5). If the targeted antigen on all of the 
CSCs is sufficiently expressed, the therapeutic agent may eradicate the relapse-causing cells and eventually stop the disease. If for example beta-particles emitted 
from 90Y or 177Lu (maximum energy, maximum range, and average linear energy transfer (LET) equal to 2.3 and 0.5 MeV, 11.3 and 1.8 mm, and 0.18 and 0.20 keV/
µm, respectively) are used as therapeutic agents, the number of hits to the CSC required to kill it would be at least in the order of 2,000. However, if alpha particles 
emitted from for example 211At or 213Bi (maximum energy, maximum range, and average LET equal to 7.4 and 8.4 MeV, 66 and 80 µm, and 125 and 120 keV/µm, 
respectively) are used instead, the number of hits required would instead be in the order of 20. This means that the likelihood of eradicating the CSCs using 
alpha-particles greatly exceeds that of using beta particles, especially if the targeted antigen is expressed in low numbers on the CSCs. It should also be noted that, 
although the range of the alpha particles is in the order of typically only two to three cell diameters, some crossfire will still occur of neighboring eventually untargeted 
cells.
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reduce SC characteristics in treated cells, including radioresist-
ance (unpublished data). Epigenetic modifications may turn 
on or off critical genes, and we have previously shown that the 
epigenetic regulator REST is downregulated in CRPC and asso-
ciated with dedifferentiation and poor prognosis (36). However, 
treatment with HDAC inhibitors in combination with RIT (such 
as TAT) may allow a more efficient treatment by epigenetically 
regulating expression of SC proteins such as ALDH enzymes and 
ABC transporters (37, 38), potentiating the effects of the alpha 
particles in the eradication of the CSC population.
ConCLUsion
This article claims that choosing TAT against CSCs might be a 
way forward to increase the probability of prolonged survival, 
or even cure, for patients having a metastatic cancerous disease. 
Castration-resistant PCa is today an incurable disease, with only a 
relatively short mean survival after progression, despite develop-
ment of new drugs during recent years targeting the bulk of the 
prostate tumor cells. Targeting the root cause of tumor recurrence 
with efficient RIT methods would most likely result in prolonged 
survival compared to the conventional treatment concepts of 
today. We think that novel alpha particle-based RIT therapies 
targeting various prostate CSC markers could transform the 
treatment of resistant metastatic PCa in the near future.
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